Literature DB >> 31897876

Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors.

Priyanka A Pophali1,2, Melissa C Larson3, Cristine Allmer3, Umar Farooq4, Brian K Link4, Matthew J Maurer3, James R Cerhan3, Carrie A Thompson5.   

Abstract

PURPOSE: Compliance with US Preventive Services Task Force (USPSTF) age-appropriate cancer screening and immunization guidelines in lymphoma survivors is not known. We sought to measure compliance in non-Hodgkin lymphoma (NHL) survivors and identify any differences based on patient, disease, and treatment characteristics.
METHODS: Eligible NHL survivors were identified from the Molecular Epidemiology Resource (MER) prospective cohort study. Survivors self-reported colorectal, breast, and prostate cancer screening and influenza immunization in a questionnaire 3 years post-diagnosis (FU3). The USPSTF guidelines were used to define compliance. Chi-square tests were used to compare characteristics of compliant versus non-compliant survivors.
RESULTS: A total of 1833 MER participants from 2005 to 2012 completed a FU3. Rates of breast and prostate cancer screening were 96% and 72%, respectively. No differences in compliance based on patient or disease characteristics or treatment were observed. Ninety-two percent of survivors were compliant with colorectal cancer screening. Older age, indolent lymphoma histology, and 2008-2012 year of diagnosis were associated with higher compliance. Eighty-two percent of survivors were compliant with influenza vaccination and older age was associated with higher compliance.
CONCLUSION: NHL survivors have high compliance with USPSTF recommendations for cancer screening and immunization. Survivors who are younger or have aggressive lymphomas are less likely to meet the colorectal cancer screening guidelines. Older survivors are more likely to receive influenza vaccination. IMPLICATIONS FOR CANCER SURVIVORS: Measures to further improve preventive care for NHL survivors, especially those younger in age, are necessary.

Entities:  

Keywords:  Cancer screening; Immunization; NHL survivors

Mesh:

Year:  2020        PMID: 31897876      PMCID: PMC7261247          DOI: 10.1007/s11764-019-00846-x

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  22 in total

1.  Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.

Authors:  Cédric Rossi; Jérémie Jégu; Morgane Mounier; Mylène Dandoit; Marc Colonna; Laetitia Daubisse-Marliac; Brigitte Trétarre; Olivier Ganry; Anne-Valérie Guizard; Simona Bara; Véronique Bouvier; Anne-Sophie Woronoff; Alain Monnereau; Olivier Casasnovas; Michel Velten; Xavier Troussard; Marc Maynadié
Journal:  Leuk Lymphoma       Date:  2015-03-08

2.  Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis.

Authors:  M Pirani; R Marcheselli; L Marcheselli; A Bari; M Federico; S Sacchi
Journal:  Ann Oncol       Date:  2011-02-10       Impact factor: 32.976

3.  Measuring Vital Signs: an IOM report on core metrics for health and health care progress.

Authors:  David Blumenthal; J Michael McGinnis
Journal:  JAMA       Date:  2015-05-19       Impact factor: 56.272

Review 4.  Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects.

Authors:  Andrea K Ng
Journal:  Blood       Date:  2014-11-27       Impact factor: 22.113

5.  Role of oncologists and primary care physicians in providing follow-up care to non-Hodgkin lymphoma survivors within 5 years of diagnosis: a population-based study.

Authors:  Laura P Forsythe; Neeraj K Arora; Catherine M Alfano; Kathryn E Weaver; Ann S Hamilton; Noreen Aziz; Julia H Rowland
Journal:  Support Care Cancer       Date:  2014-01-12       Impact factor: 3.603

6.  Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors.

Authors:  G Sanna; K Lorizzo; N Rotmensz; V Bagnardi; S Cinieri; M Colleoni; F Nolè; A Goldhirsch
Journal:  Ann Oncol       Date:  2006-11-06       Impact factor: 32.976

7.  Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.

Authors:  Andrea K Ng; Judy E Garber; Lisa R Diller; Robyn L Birdwell; Yang Feng; Donna S Neuberg; Barbara Silver; David C Fisher; Karen J Marcus; Peter M Mauch
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

8.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

Authors:  Lorry G Rubin; Myron J Levin; Per Ljungman; E Graham Davies; Robin Avery; Marcie Tomblyn; Athos Bousvaros; Shireesha Dhanireddy; Lillian Sung; Harry Keyserling; Insoo Kang
Journal:  Clin Infect Dis       Date:  2014-02       Impact factor: 9.079

9.  Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Tara Seshadri; Melania Pintilie; John Kuruvilla; Armand Keating; Richard Tsang; Sahar Zadeh; Michael Crump
Journal:  Leuk Lymphoma       Date:  2009-03

10.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.